Oral Nicorandil to Reduce Cardiac Death After Coronary Revascularization in Hemodialysis Patients: A Randomized Trial

American Journal of Kidney Diseases

Volumn 54, Issue 2, 2009, Pages 307-317

  Nishimura, Masato ^a   Tokoro, Toshiko ^a   Nishida, Masasya ^a   Hashimoto, Tetsuya ^a   Kobayashi, Hiroyuki ^a   Imai, Ryo ^a   Yamazaki, Satoru ^b   Okino, Koji ^c   Iwamoto, Noriyuki ^a   Takahashi, Hakuo ^d   Ono, Toshihiko ^a  

^a Toujinkai Hospital   (Japan)

^b Toujinkai Clinic   (Japan)

^c Toujinkai Satellite Clinic   (Japan)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

End stage renal disease; ischemia; microcirculation; potassium channel; preconditioning; sudden death

Indexed keywords

ADENOSINE TRIPHOSPHATASE; NICORANDIL; NITRATE; POTASSIUM CHANNEL STIMULATING AGENT;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEADACHE; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HUMAN; INTERVENTION STUDY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SUDDEN DEATH; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DEATH, SUDDEN, CARDIAC; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NICORANDIL; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RENAL DIALYSIS; VASODILATOR AGENTS;

EID: 67650386148     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.03.025     Document Type: Article

References (42)

1. Szczech L.A., Reddan D.N., Owen W.F., et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 60 (2001) 292-299
2. Le Feuvre C., Dambrin G., Helft G., et al. Clinical outcome following angioplasty in dialysis patients: A case-control study in the era of coronary stenting. Heart 85 (2001) 556-560
3. Hemmelgarn B.R., Southern D., Culleton B.F., et al. Survival after coronary revascularization among patients with kidney disease. Circulation 110 (2004) 1890-1895
4. Herzog C.A., Ma J.Z., and Collins A.J. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 106 (2002) 2207-2211
5. Hemmelgarn B.R., Ghali W.A., Quan H., et al. Poor long-term survival after coronary angiography in patients with renal insufficiency. Am J Kidney Dis 37 (2001) 64-72
6. Ting H.H., Tahirkheli N.K., Berger P.B., et al. Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. Am J Cardiol 87 (2001) 630-633
7. Nishimura M., Tokoro T., Nishida M., et al. Association of insulin resistance with de novo coronary stenosis after percutaneous coronary artery intervention in hemodialysis patients. Nephron Clin Pract 109 (2008) c9-c17
8. Taira N., Satoh K., Yanagisawa T., Imai Y., and Hiwatari M. Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75). Clin Exp Pharmacol Physiol 6 (1979) 301-316
9. Kukovetz W.R., Holzmann S., Braida C., and Pöch G. Dual mechanism of the relaxing effect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization. J Cardiovasc Pharmacol 17 (1991) 627-633
10. Taira N. Nicorandil is a hybrid between nitrates and potassium channel activators. J Cardiol 63 (1989) 18J-24J
11. Lee T.M., Su S.F., Chou T.F., Lee Y.T., and Tsai C.H. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation 105 (2002) 334-340
12. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: The Impact Of Nicorandil in Angina (IONA) randomized trial. Lancet 359 (2002) 1269-1275
13. Nishimura M., Tokoro T., Nishida M., et al. Clinical potential of nicorandil to inhibit major cardiac events in hemodialysis patients with suspected myocardial ischemia. Nephron Clin Pract 111 (2009) c212-c221
14. Ishii H., Toriyama T., Aoyama T., et al. Efficacy of oral nicorandil in patients with end-stage renal disease: A retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther 29 (2007) 1-13
15. Nishimura M., Hashimoto T., Kobayashi H., et al. Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int 66 (2004) 811-819
16. Nishimura M., Tsukamoto K., Hasebe N., et al. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol 51 (2008) 139-145
17. Nishimura M., Murase M., Hashimoto T., et al. Insulin resistance and impaired myocardial fatty acid metabolism in dialysis patients with normal coronary arteries. Kidney Int 69 (2006) 553-559
18. Sahn D.J., DeMaria A., Kisso J., and Weyman A. The Committee on M-mode Standardization of the American Society of Echocardiography: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
19. Demirovic J., and Myerburg R.J. Epidemiology of sudden coronary death: An overview. Prog Cardiovasc Dis 37 (1994) 39-48
20. Amann K., Neusüss R., Ritz E., Irzyniec T., Wiest G., and Mall G. Changes in vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 8 (1995) 409-417
21. Barenbrock M., Spieker C., Laske V., et al. Studies of vessel wall properties in hemodialysis patients. Kidney Int 45 (1994) 1397-1400
22. Törnig J., Gross M.L., Simonaviciene A., Mall G., Ritz E., and Amann K. Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure. J Am Soc Nephrol 10 (1999) 77-83
23. Amann K., Breitbach M., Ritz E., and Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9 (1998) 1018-1022
24. Topol E.J., and Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101 (2000) 570-580
25. Kotani J., Mintz G.S., Pregowski J., et al. Volumetric intravascular ultrasound evidence that distal embolization during acute infarct intervention contributes to inadequate myocardial perfusion grade. Am J Cardiol 92 (2003) 728-732
26. Henriques J.P., Zijlstra F., Ottervanger J.P., et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 23 (2002) 1112-1117
27. Hamburger W.W., Priest W.S., Bettman R.B., and Howard H.C. Experimental coronary embolism. Am J Med Sci 171 (1926) 168-184
28. Agress C.M., Rosenberg M.J., Jacobs H.I., Binder M.J., Schneiderman A., and Clark W.G. Protracted shock in the closed-chest dog following coronary embolization with graded microspheres. Am J Physiol 170 (1952) 536-549
29. Marcus E., Katz L.N., Pick R., and Stamler J. The production of myocardial infarction: Chronic coronary insufficiency and chronic coronary heart disease in the dog. Acta Cardiol 13 (1958) 536-549
30. Jacoby J.A., Taylor W.J., Smith G.T., Gorlin R., and Harken D.E. A new therapeutic approach to acute coronary occlusion with microspheres. Am J Cardiol 9 (1962) 60-73
31. Bing R.J., Castellanos A., Gradel E., Lupton C., and Siegel A. Experimental myocardial infarction: Circulatory biochemical and pathologic changes. Am Med Sci 232 (1956) 533-554
32. Akai K., Wang Y., Sato K., et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: Its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol 26 (1995) 541-547
33. Kasama S., Toyama T., Hatori T., et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. Am Heart J 150 (2005) 477
34. Miyazaki T., Moritani K., Miyoshi S., et al. Nicorandil augments regional ischemia-induced monophasic action potential shortening and potassium accumulation without serious proarrhythmia. J Cardiovasc Pharmacol 26 (1995) 949-956
35. Sakamoto T., Kaikita K., Miyamoto S., et al. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease. Circ J 68 (2004) 232-235
36. Nagata K., Obata K., Odashima M., et al. Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation of mitochondrial ATP-sensitive potassium channels and a nitrate-like effect. J Mol Cell Cardiol 35 (2003) 1505-1512
37. Furukawa K., Itoh T., Kajiwara M., et al. Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guinea-pig coronary artery. J Pharmacol Exp Ther 218 (1981) 248-259
38. Kawano K., and Yamaguchi M. Absorption and filtration of nicorandil with various types of dialytic membranes. Igaku To Yakugaku 41 (1999) 1137-1141
39. Frydman A.M. Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol 20 suppl 3 (1992) S34-S44
40. Simpson D., and Wellington K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs 64 (2004) 1941-1955
41. Zhu W.-L., Shan Y.-D., Guo J.-X., et al. Double-blind, multicenter, active controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J 71 (2007) 826-833
42. Molinaro M., Villa G., Regazzi M.B., et al. Pharmacokinetics of nicorandil in patients with normal and impaired renal function. Eur J Clin Pharmacol 42 (1992) 203-207